MedTrace Logo

Follow on Extension of XT-150-1-0201

NCT03769662 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-01-18

No results posted yet for this study

Summary

XT-150 safety and efficacy in severe osteoarthritic pain.

Conditions

  • Osteoarthritis, Knee

Interventions

BIOLOGICAL

XT-150

IL-10 transgene DNA plasmid injected into the knee synovial capsule

Sponsors & Collaborators

  • Xalud Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Mark Rickman, MD · University of Adelaide

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-20
Primary Completion
2019-10-30
Completion
2019-12-30
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03769662 on ClinicalTrials.gov